https://linkintime.co.in/mipo/ipoallotment.html
Still awaiting
Hi Rikin,
Darolutamide has 7 intermediates. Ami has signed contract for ~3 molecules so far with Fermion (no confirmation on whether all of them are for Darolutamide). Can you share your basis of 500cr-600cr?
Wait for one order from PSUs like NTPC and this company will be in another orbit. They did get NTPC order in KPEL
Disclosure, I am invested now at 300 levels.
https://caqm.nic.in/WriteReadData/LINKS/RCP2f4b7e21-b29c-44bf-b7d6-a1b1c2610f03.pdf
Update on 0.4 million ton allocation…
DCM Shriram Industries Limited Demerger/Spin-off/ Restructuring:
Simple Words:
The plan involves:
Merging with Lily Commercial Private Limited: This is a private company that invests in the Company and is owned by the same promoters. The Company will issue new shares to the shareholders of Lily Commercial Private Limited in exchange for their shares. This will simplify the promoter shareholding structure and eliminate shareholding tiers.
Demerging into three separate companies: The Company will split its three business verticals, i.e., chemical, rayon, and sugar, into three different companies. The chemical business will go to DCM Shriram Fine Chemicals Limited, the rayon business (including defense and engineering projects) will go to DCM Shriram International Limited, and the sugar business (including alcohol and power) will remain with the Company. The shareholders of the Company will get an equal number of shares in each of the three companies. This will allow each business to have more focus, efficiency, flexibility, and growth potential.
So, After this restructuring, there will be 3 separate companies:
1. DCM Shriram Fine Chemicals Limited. { will have the chemical business.}
2. DCM Shriram International Limited. { the rayon business (including defense and engineering projects)}
3. DCM Shriram Industries Limited. { the sugar business (including alcohol and power)}
Share exchange ratio: The Company will issue equity shares to the shareholders of the Transferor Company and the Resultant Companies in the ratio of 1:1 and 1:1, respectively, based on the valuation reports and fairness opinions provided by independent valuers and consultants.
Rationale for the Scheme: The Scheme is expected to provide greater management focus, operational efficiency, financial flexibility, shareholder value, and business growth for each of the demerged undertakings, as well as streamlining the promoter shareholding and facilitating succession planning.
Approvals and disclosures: The Scheme is subject to the approvals of the shareholders, creditors, regulators, and tribunals of the companies involved in the Scheme, and the disclosures required under the applicable laws and regulations. The Resultant Companies are proposed to be listed on the stock exchanges upon the completion of the Scheme.
Please advise the Author?
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!